InvestSMART

Radiopharm Theranostics Limited (ASX:RAD)

ALERT: Price-sensitive ASX Announcement for RAD
Current share price for RAD : $0.006 -0.005 (-42.86%)+
Announcement
Release
26 Aug 2026 8:59AM
Price at Release
$0.011
Full Release
download
Summary
Radiopharm Theranostics Limited announced the dosing of the first patient in the second cohort of its Phase 1/2a clinical trial for BetaBart (RV-01), a radiopharmaceutical therapeutic targeting B7-H3 expressing solid tumors. The trial, conducted in the U.S., aims to assess the safety, biodistribution, and preliminary anti-tumor activity of RV-01. With a focus on oncology radiopharmaceuticals, Radiopharm Theranostics is advancing this study to determine the optimal dose for future studies, following positive recommendations from the Safety and Monitoring Committee. The trial is part of a joint venture with MD Anderson Cancer Center.
Key Points
  • Radiopharm Theranostics doses the first patient in the second cohort of BetaBart (RV-01) clinical trial.
  • The trial is a Phase 1/2a study focused on B7-H3 expressing solid tumors.
  • RV-01 is a 177Lutetium-conjugated therapeutic targeting B7-H3, a molecule overexpressed in various tumor types.
  • The clinical trial aims to evaluate the safety, biodistribution, and anti-tumor activity of RV-01.
  • The trial is conducted at clinical centers across the U.S.
  • Phase 1/2a study will determine the recommended dose for future studies.
  • Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on oncology radiopharmaceuticals.
  • The study aims to enroll 61 participants with a history of various confirmed cancers.
  • The 70 mCi dose level was recommended by the Safety and Monitoring Committee.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.